Evidence map›Paper›PMID 38633652›Full record

ReviewHeliyon2024

Polyrhodanine-based nanomaterials for biomedical applications: A review.

Ibrahim Huzyan Hiba, Jin Kwei Koh, Chin Wei Lai, Seyyed Mojtaba Mousavi, Irfan Anjum Badruddin, Mohamed Hussien, Jest Phia Wong

Abstract readReview
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ibrahim Huzyan HibaNanotechnology and Catalysis Research Centre (NANOCAT), Institute for Advanced Studies (IAS), University of Malaya (UM), 50603, Kuala Lumpur, Malaysia.
Jin Kwei KohNanotechnology and Catalysis Research Centre (NANOCAT), Institute for Advanced Studies (IAS), University of Malaya (UM), 50603, Kuala Lumpur, Malaysia.
Chin Wei LaiNanotechnology and Catalysis Research Centre (NANOCAT), Institute for Advanced Studies (IAS), University of Malaya (UM), 50603, Kuala Lumpur, Malaysia.
Seyyed Mojtaba MousaviDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taiwan.
Irfan Anjum BadruddinMechanical Engineering Department, College of Engineering, King Khalid University, Abha, 61421, Saudi Arabia.
Mohamed HussienDepartment of Chemistry, Faculty of Science, King Khalid University, P.O. Box 9004, Abha, 61413, Saudi Arabia.
Jest Phia WongHarper Elite Sdn Bhd, UG-23, PJ Midtown, Jalan Kemajuan, Seksyen 13, 46200, Petaling Jaya, Selangor Darul Ehsan, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhodanine is a heterocyclic organic compound that has been investigated for its potential biomedical applications, particularly in drug discovery. Rhodanine derivatives have been examined as the medication options for numerous illnesses, including cancer, inflammation, and infectious diseases. Some rhodanine derivatives have also shown promising activity against drug-resistant strains of bacteria and viruses. One of these derivatives is polyrhodanine (PR), a conducting polymer that has gained attention for its biomedical properties. This review article summarises the latest advancements in creating biomaterials based on PR for biosensing, antimicrobial treatments, and anticancer therapies. The distinctive characteristics of PR, such as biocompatibility, biodegradability, and good conductivity, render it an attractive candidate for these applications. The article also explores obstacles and potential future paths for advancing biomaterials made with PR, including synthesis modifications, characterisation techniques, and in vivo evaluation of biocompatibility and efficacy. Overall, as an emerging research topic, this review emphasises the potential of PR as a promising biomaterial for various biomedical applications and provides insights into the contemporary state of research and prospective directions for investigation.

Identifiers

PMID38633652
PMCPMC11021909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.